Orexigen Therapeutics Inc (OREX)

3.37
NASDAQ : Health Care
Prev Close 3.61
Day Low/High 3.08 / 3.62
52 Wk Low/High 1.65 / 6.49
Avg Volume 413.80K
Exchange NASDAQ
Shares Outstanding 11.25M
Market Cap 40.60M
EPS -1.70
Div & Yield N.A. (N.A)

Latest News

Orexigen Therapeutics Announces Publication Of Contrave® (naltrexone HCl And Bupropion HCl Extended-release Tablets) Real-World Study Results In

Orexigen Therapeutics Announces Publication Of Contrave® (naltrexone HCl And Bupropion HCl Extended-release Tablets) Real-World Study Results In "Obesity"

-- IGNITE study showed Contrave combined with a commercially-available weight loss program yielded nearly 10 percent body weight loss that persisted for 78 weeks --

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade several under-$10 stocks that are poised for breakouts.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under -$10 stocks are poised to breakout and trade higher from current levels.

Orexigen Announces South Korean Approval Of Contrave® (naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients

Orexigen Announces South Korean Approval Of Contrave® (naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients

Orexigen has shipped the first order of Contrave tablets to partner Kwang Dong in anticipation of a commercial launch later this quarter

Orexigen Announces Strategic Acquisition Of All U.S. Rights To Contrave®, The Market Leading Branded Anti-obesity Prescription Medicine

Orexigen Announces Strategic Acquisition Of All U.S. Rights To Contrave®, The Market Leading Branded Anti-obesity Prescription Medicine

Acquisition magnifies projected long-term corporate profitability and opens multiple paths for shareholder value creation

Orexigen And Takeda Jointly Announce Orexigen's Acquisition Of All Rights To CONTRAVE® In The United States

Orexigen And Takeda Jointly Announce Orexigen's Acquisition Of All Rights To CONTRAVE® In The United States

Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets

Orexigen Therapeutics (OREX) Stock Plunges on Q4 Miss

Orexigen Therapeutics (OREX) Stock Plunges on Q4 Miss

Orexigen Therapeutics (OREX) stock is falling on Friday morning after the company posted its 2015 fourth quarter results before today’s market open.